Estimating clinically significant differences in quality of life outcomes

被引:374
作者
Wyrwich, KW [1 ]
Bullinger, M
Aaronson, N
Hays, RD
Patrick, DL
Symonds, T
机构
[1] St Louis Univ, St Louis, MO 63103 USA
[2] Univ Hamburg, Clin Eppendorf, Dept Psychol Med, Hamburg, Germany
[3] Netherlands Canc Inst, Div Psychosocial Res, Amsterdam, Netherlands
[4] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
[5] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA
[6] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA
[7] Pfizer Ltd, Outcomes Res Dept, Sandwich CT14 9PD, Kent, England
关键词
clinically important change; clinical significance; minimally important difference; quality of life;
D O I
10.1007/s11136-004-0705-2
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Objective: This report extracts important considerations for determining and applying clinically significant differences in quality of life (QOL) measures from six published articles written by 30 international experts in the field of QOL assessment and evaluation. The original six articles were presented at the Symposium on Clinical Significance of Quality of Life Measures in Cancer Patients at the Mayo Clinic in April 2002 and subsequently were published in Mayo Clinic Proceedings. Principal findings: Specific examples and formulas are given for anchor-based methods, as well as distribution-based methods that correspond to known or relevant anchors to determine important differences in QOL measures. Important prerequisites for clinical significance associated with instrument selection, responsiveness, and the reporting of QOL trial results are provided. We also discuss estimating the number needed to treat (NNT) relative to clinically significant thresholds. Finally, we provide a rationale for applying group-derived standards to individual assessments. Conclusions: While no single method for determining clinical significance is unilaterally endorsed, the investigation and full reporting of multiple methods for establishing clinically significant change levels for a QOL measure, and greater direct involvement of clinicians in clinical significance studies are strongly encouraged.
引用
收藏
页码:285 / 295
页数:11
相关论文
共 58 条
[1]  
Anastasi A., 1997, Psychological testing
[2]  
[Anonymous], QUALITY LIFE PHARMAC
[3]   Understanding changes in health status - Is the floor phenomenon merely the last step of the staircase? [J].
Baker, DW ;
Hays, RD ;
Brook, RH .
MEDICAL CARE, 1997, 35 (01) :1-15
[4]   Impact of the global on patient perceivable change in an asthma specific QOL questionnaire [J].
Barber, BL ;
Santanello, NC ;
Epstein, RS .
QUALITY OF LIFE RESEARCH, 1996, 5 (01) :117-122
[5]   MEASURING HEALTH CHANGES AMONG SEVERELY ILL PATIENTS - THE FLOOR PHENOMENON [J].
BINDMAN, AB ;
KEANE, D ;
LURIE, N .
MEDICAL CARE, 1990, 28 (12) :1142-1152
[6]   A COMPARISON OF HEALTH-RELATED QUALITY-OF-LIFE MEASURES FOR RHEUMATOID-ARTHRITIS RESEARCH [J].
BOMBARDIER, C ;
RABOUD, J .
CONTROLLED CLINICAL TRIALS, 1991, 12 (04) :S243-S256
[7]   What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) study 5592 [J].
Cella, D ;
Eton, DT ;
Fairclough, DL ;
Bonomi, P ;
Heyes, AE ;
Silberman, C ;
Wolf, MK ;
Johnson, DH .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2002, 55 (03) :285-295
[8]   Group vs individual approaches to understanding the clinical significance of differences or changes in quality of life [J].
Cella, D ;
Bullinger, M ;
Scott, C ;
Barofsky, I .
MAYO CLINIC PROCEEDINGS, 2002, 77 (04) :384-392
[9]  
Cohen J., 1988, STAT POWER ANAL BEHA
[10]   REPRODUCIBILITY AND RESPONSIVENESS OF HEALTH-STATUS MEASURES - STATISTICS AND STRATEGIES FOR EVALUATION [J].
DEYO, RA ;
DIEHR, P ;
PATRICK, DL .
CONTROLLED CLINICAL TRIALS, 1991, 12 (04) :S142-S158